FTRE Fortrea Holdings Inc.
Services-Medical Laboratories · Nasdaq · SEC CIK 1965040 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-3.4%
TTM net income YoY93.2%
TTM EPS YoY94.1%
Revenue 3-yr CAGR-2.7%
Net income 3-yr CAGR—
Margins
Gross margin20.0%
Operating margin0.5%
Net margin-2.6%
FCF margin6.3%
EBITDA margin3.4%
Returns
ROE-12.3%
ROA-2.5%
ROIC (approx.)0.7%
Asset turnover0.97x
Leverage & solvency
Liabilities / assets80.6%
Debt / equity1.98x
Current ratio0.97x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-2.94x
Accruals ratio-9.9%
Payout ratio—
Capex / revenue1.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $691.50M | $678.20M | $636.50M | $660.50M | $701.30M | $710.30M | $651.30M | $697.00M |
| Cost of revenue | $552.00M | $539.00M | $512.90M | $529.40M | $578.60M | $576.80M | $534.80M | $556.10M |
| Gross profit | $139.50M | $139.20M | $123.60M | $131.10M | $122.70M | $133.50M | $116.50M | $140.90M |
| SG&A expense | $103.80M | $102.10M | $100.50M | $103.00M | $106.80M | $124.80M | $121.80M | $148.10M |
| Operating income | $15.00M | $14.80M | -$3.40M | -$13.60M | -$8.60M | -$330.30M | -$520.10M | -$55.60M |
| Pretax income | -$3.60M | -$1.20M | -$12.30M | -$35.60M | -$28.70M | -$370.70M | -$548.00M | -$74.90M |
| Income tax | -$4.20M | $12.00M | $11.30M | -$3.10M | -$12.80M | $4.20M | $14.90M | -$1.00M |
| Net income | $600,000 | -$13.20M | -$23.60M | -$32.50M | -$15.90M | -$374.90M | -$562.90M | -$61.20M |
| EBITDA | $35.00M | $34.40M | $16.40M | $5.70M | $11.00M | -$310.70M | -$500.60M | -$34.80M |
| EPS (basic) | 0.01 | -0.14 | -0.25 | — | -0.17 | -4.14 | -6.25 | — |
| EPS (diluted) | 0.01 | -0.14 | -0.25 | — | -0.17 | -4.14 | -6.25 | — |
| Weighted avg. shares (diluted) | 101.20M | 94.80M | 93.60M | — | 91.20M | 90.60M | 90.10M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $220.60M | $168.60M | $147.50M | $174.60M | $131.30M | $81.20M | $101.60M | $118.50M |
| Current assets | $952.70M | $923.60M | $881.50M | $897.20M | $918.50M | $960.00M | $970.30M | $948.20M |
| Goodwill | $949.90M | $950.30M | $950.80M | $960.00M | $958.10M | $965.20M | $1.24B | $1.71B |
| Intangibles | $572.00M | $586.80M | $601.70M | $622.00M | $635.40M | $654.30M | $651.30M | $655.70M |
| Total assets | $2.74B | $2.71B | $2.68B | $2.72B | $2.74B | $2.84B | $3.12B | $3.58B |
| Current liabilities | $983.30M | $963.70M | $929.10M | $913.30M | $914.40M | $942.30M | $999.10M | $949.50M |
| Short-term debt | $23.40M | $17.10M | $10.90M | $4.80M | $74.50M | $74.80M | $163.80M | $74.80M |
| Long-term debt | $1.03B | $1.04B | $1.04B | $1.05B | $1.05B | $1.10B | $1.05B | $1.05B |
| Total debt | $1.06B | $1.05B | $1.05B | $1.05B | $1.13B | $1.18B | $1.21B | $1.12B |
| Total liabilities | $2.21B | $2.19B | $2.16B | $2.15B | $2.16B | $2.25B | $2.26B | $2.22B |
| Shareholders' equity | $532.30M | $524.20M | $525.90M | $563.50M | $580.80M | $589.20M | $858.80M | $1.36B |
| Net debt | $834.70M | $885.70M | $906.00M | $878.20M | $995.30M | $1.09B | $1.11B | $1.01B |
| Shares outstanding | 96.50M | 95.10M | 94.60M | 93.10M | 92.20M | 90.80M | 90.50M | 89.70M |
| Cash flow statement | ||||||||
| Operating cash flow | $60.80M | $28.90M | -$17.00M | $129.10M | $86.80M | $21.80M | -$124.20M | $17.10M |
| Capital expenditure | $8.30M | $9.00M | $8.00M | $7.50M | $7.30M | $7.50M | $2.90M | -$3.20M |
| Free cash flow | $52.50M | $19.90M | -$25.00M | $121.60M | $79.50M | $14.30M | -$127.10M | $20.30M |
| Investing cash flow | -$8.30M | -$7.00M | -$8.00M | -$7.50M | $13.30M | -$7.50M | $16.10M | $3.50M |
| Financing cash flow | $0 | $0 | $0 | -$75.70M | -$50.00M | -$39.00M | $88.40M | -$1.10M |
| Depreciation & amortization | $20.00M | $19.60M | $19.80M | $19.30M | $19.60M | $19.60M | $19.50M | $20.80M |
| Stock-based compensation | $12.00M | $12.60M | $11.40M | $14.80M | $22.30M | $22.70M | $14.60M | $15.30M |
Free plan shows the latest 8 periods; Pro shows all 19 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.